PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892 on ClinicalTrials.gov · last registry update 2026-04-13
An unusually large phase 4: 6,000 participants, more than double the 75 typical for the stage. Due to report 1 March 2029, alongside 11 other tracked readouts that quarter. Primary outcome, as filed: Total (first and recurrent) cardiovascular, kidney, and death events. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 26 September 2022 — 4 years so far.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Brigham and Women's Hospital
- Sponsor type
- Other
- Enrollment
- 6,000
- Started
- 2022-09-26
- Primary completion
- 2029-03-01 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Total (first and recurrent) cardiovascular, kidney, and death events
Conditions studied
Type2Diabetes · ASCVD
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.